+34 93 402 04 56 info@proteodesign.es

Barcelona, Spain February 28, 2018 ProteoDesign, a biotech spin-out from Princeton University developing personalized immunotherapies in cancer, today announced the successful closing of a 1.7M€ financing round. The company has a novel proprietary platform for protein engineering, discovered after more than 20 years of pioneering research in the field. Proceeds from the financing will be used to advance ProteoDesign immunotherapy candidates through preclinical development.

The financing round was led by existing investor Caixa Capital Risc and joined by an undisclosed private investor.